Skip to main content
Apontis Pharma AG logo

Apontis Pharma AG — Investor Relations & Filings

Ticker · APPH ISIN · DE000A3CMGM5 LEI · 894500ETO1J6MR8PDF91 F Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2021-12-16 Board/Management Inform…
Country DE Germany
Listing F APPH

About Apontis Pharma AG

https://apontis-pharma.de/en/

Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.

Recent filings

Filing Released Lang Actions
APONTIS PHARMA strengthens management for future growth: Thomas Zimmermann appointed new CFO
Board/Management Information Classification · 1% confidence The document is a news release dated December 16, 2021, announcing a specific personnel change: the appointment of Thomas Zimmermann as the new Chief Financial Officer (CFO) of APONTIS PHARMA AG. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The presence of DGAP-News headers and the focus on personnel confirm this classification over general regulatory filings or earnings releases.
2021-12-16 English
APONTIS PHARMA and Midas Pharma announce development partnership to launch Single Pill with pan-European intellectual property rights
Regulatory Filings Classification · 1% confidence The document is a press release format, indicated by the 'DGAP-News' header, the date/time stamp, and the structure typical of corporate news dissemination services (like EQS Group AG mentioned at the end). The content announces a 'development partnership' and 'product launch' strategy update between two pharmaceutical companies regarding intellectual property rights and future product development (a Single Pill for hypertension). This type of announcement, detailing strategic business developments, partnerships, and pipeline updates, is generally classified as a general corporate announcement or news release. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a specific regulatory filing like Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate general category for significant, non-financial-statement corporate news that doesn't fit other specific codes is 'Regulatory Filings' (RNS) as a broad corporate announcement category, or potentially 'Capital/Financing Update' (CAP) if the partnership is viewed as a strategic financing/development move, but RNS is safer for general news releases. Reviewing the definitions, this is a strategic business announcement about a partnership and product development, not a formal financial report, management change, or shareholder vote result. It fits best under the general regulatory announcement/news category, RNS, as it is a 'Corporate News' item distributed via a regulatory service.
2021-12-14 English
APONTIS PHARMA grows significantly faster than the overall market in the nine-month period 2021 - Revenue forecast increased
Earnings Release Classification · 1% confidence The document is titled with a date and key performance indicators (KPIs) for the 'nine-month period 2021' (9M 2021). It explicitly mentions 'Quarterly / Interim Statement/9 Month figures' in the keywords section. It contains condensed consolidated income statements, balance sheets, and cash flow statements for the 9-month period, although it notes the figures are unaudited. This structure strongly indicates a comprehensive financial report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it provides detailed financial tables, not just highlights, and it is not a 10-K as it covers only nine months. 9M 2021
2021-11-18 English
9M Präsentation (EN)
Investor Presentation Classification · 1% confidence The document is titled "9M 2021 Results" and contains detailed financial highlights (EURm 36.1 revenues, EURm 4.4 EBITDA adj.), management presentations, strategic updates, pipeline information, and references to a recent IPO. This structure, focusing on performance over a nine-month period and presented in a slide deck format (implied by the structure and content), strongly indicates an Investor Presentation (IP) or a Management Discussion & Analysis (MDA) accompanying interim results. Since it is a presentation format detailing results, strategy, and pipeline, 'Investor Presentation' (IP) is the most fitting category. It is not a full Annual Report (10-K) or a standalone Earnings Release (ER) which is usually just the press release highlights. It is more comprehensive than an ER.
2021-11-18 German
9M Results Presentation
Investor Presentation Classification · 1% confidence The document is titled "9M 2021 Results" and contains detailed financial highlights (EURm 36.1 revenues, EURm 4.4 EBITDA adj.), management presentations, strategic updates, pipeline information, and references to a recent IPO. This structure, focusing on performance over a nine-month period and presented in a slide deck format (implied by the structure and content), strongly indicates an Investor Presentation (IP) or a Management Discussion & Analysis (MDA) accompanying interim results. Since it is a presentation format detailing results, strategy, and pipeline, 'Investor Presentation' (IP) is the most fitting category. It is not a full Annual Report (10-K) or a standalone Earnings Release (ER) which is usually just the press release highlights. It is more comprehensive than an ER.
2021-11-18 English
APONTIS PHARMA announces market launch of new Single Pill
Regulatory Filings Classification · 1% confidence The document is a press release dated October 26, 2021, announcing a product launch ('market launch of new Single Pill') and an in-licensing agreement. It contains key highlights, future plans (launch in Q2 2022), and company boilerplate information. This format is characteristic of an initial announcement of financial or operational news, rather than a comprehensive report (like 10-K or IR) or a transcript (CT). It fits best under the Earnings Release (ER) category, which covers initial announcements of periodical results or significant operational milestones, or potentially Regulatory Filings (RNS) if it were purely regulatory. Given the focus on a product launch and market expansion, ER is the most appropriate fit among the specific operational/financial announcement codes, although it is not strictly an earnings report. Since it is a news announcement disseminated via DGAP, and it is not a formal financial report, ER (Earnings Release, often used broadly for key operational news) or RNS (Regulatory Filings/General Announcement) are the closest. Since it details a significant business development (product launch/in-licensing), ER is chosen over the generic RNS, as it conveys material operational news.
2021-10-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.